Johnson & Johnson (NYSE:JNJ) has been assigned a $153.00 price objective by analysts at Jefferies Group in a report issued on Friday. The brokerage presently has a “buy” rating on the stock. Jefferies Group’s price target points to a potential upside of 17.30% from the stock’s previous close.
JNJ has been the subject of several other research reports. Vetr lowered Johnson & Johnson from a “hold” rating to a “sell” rating and set a $124.55 price target for the company. in a research note on Thursday, April 5th. JPMorgan Chase lowered Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 2nd. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $145.00 price target for the company in a research note on Wednesday. BTIG Research restated a “sell” rating and issued a $110.00 price target on shares of Johnson & Johnson in a research note on Wednesday, January 24th. Finally, TheStreet lowered Johnson & Johnson from an “a” rating to a “c+” rating in a research note on Monday, March 26th. Five equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $144.03.
NYSE JNJ opened at $130.43 on Friday. The stock has a market cap of $347,784.63, a price-to-earnings ratio of 17.87, a P/E/G ratio of 2.06 and a beta of 0.74. Johnson & Johnson has a fifty-two week low of $120.95 and a fifty-two week high of $148.32. The company has a quick ratio of 1.12, a current ratio of 1.41 and a debt-to-equity ratio of 0.51.
In other Johnson & Johnson news, VP Paulus Stoffels sold 155,342 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the completion of the sale, the vice president now directly owns 357,906 shares in the company, valued at approximately $46,477,673.16. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.22% of the stock is currently owned by insiders.
A number of large investors have recently bought and sold shares of JNJ. Vanguard Group Inc. boosted its holdings in shares of Johnson & Johnson by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after purchasing an additional 3,023,110 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Johnson & Johnson by 2.6% during the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after purchasing an additional 4,332,612 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Johnson & Johnson by 0.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 36,594,054 shares of the company’s stock worth $4,757,593,000 after purchasing an additional 130,437 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Johnson & Johnson by 3.2% during the 4th quarter. Geode Capital Management LLC now owns 30,521,157 shares of the company’s stock worth $4,256,109,000 after purchasing an additional 939,488 shares during the last quarter. Finally, FMR LLC boosted its holdings in shares of Johnson & Johnson by 5.9% during the 2nd quarter. FMR LLC now owns 27,237,648 shares of the company’s stock worth $3,603,268,000 after purchasing an additional 1,509,745 shares during the last quarter. Institutional investors own 67.24% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Jefferies Group Analysts Give Johnson & Johnson (JNJ) a $153.00 Price Target” was originally published by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://dakotafinancialnews.com/2018/04/13/jefferies-group-analysts-give-johnson-johnson-jnj-a-153-00-price-target.html.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.